In addition to promoting osteoclasts in the pre-metastatic niche, our data also suggests that ST6GAL1 enhances the development of M2 like macrophages and can also regulate sialoglycans on prostate cancer cells that engage Siglec receptors. This evidence concerns the gene ST6GAL1 and prostate carcinoma.